Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab Ozogamicin in Children and Young Adults With Relapsed or Refractory CD22+ B-ALL
NCT02981628Phase 2Active, not recruiting
- Sponsor
- Children's Oncology Group
- Start
- Jun 2017
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of inotuzumab ozogamicin in B cell acute lymphoblastic leukemia (B-ALL) and B-cell lymphoblastic lymphoma (B-LBL) (2 cohorts), sponsored by Children's Oncology Group. Primary endpoint: Morphologic response (complete response [CR] + incomplete hematologic recovery [CRi]) at 28 days. Started Jun 2017; status: active, not recruiting.
02
Drugs
inotuzumab ozogamicin
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B-cell lymphoblastic lymphoma (B-LBL)
Beyond the preview
Go deeper on NCT02981628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02981628.